AK 131
Alternative Names: AK-131Latest Information Update: 02 Feb 2024
At a glance
- Originator Akeso Biopharma
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action 5-nucleotidase inhibitors; Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 10 Jan 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in China (IV) (NCT06166888)
- 26 Dec 2023 Phase-I clinical trials in Solid tumours (Monotherapy, Late-stage disease) in China (Parenteral) (prior to December 2023) (Akeso Biopharma Pipeline, December 2023)
- 12 Dec 2023 Akeso plans a phase Ia/Ib trial in solid tumours (Late stage disease) in China (IV) (NCT06166888)